EARLY MORTALITY IN LANGERHANS CELL HISTIOCYTOSIS III (LCH-III) TRIAL SUGGESTS SOME PATIENTS REQUIRE MORE EFFECTIVE THERAPY EVEN BEFORE THE 1ST RESPONSE ASSESSMENT POINT AT 6 WEEKS

被引：0

作者：

Visser, Johannes ^{[1
]}

Potschger, Ulrike ^{[2
]}

Thiem, Elfriede ^{[2
]}

Minkov, Milen ^{[2
]}

Arico, Maurizio ^{[3
]}

Astigarraga, Itziar ^{[4
]}

Braier, Jorge ^{[5
]}

Donadieu, Jean ^{[6
]}

Grois, Nicole ^{[2
]}

Gadner, Helmut ^{[2
]}

Henter, Jan-Inge ^{[7
]}

Janka-Schaub, Gritta ^{[8
]}

McClain, Kenneth ^{[9
]}

Weitzman, Sheila ^{[10
]}

Windebank, Kevin ^{[11
]}

Ladisch, Stephan ^{[12
]}

机构：

[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[2] Childrens Canc Res Inst, Vienna, Austria

[3] Univ Anna Meyer, Florence, Italy

[4] Hosp Univ Cruces, Bilbao, Spain

[5] Hosp Nacl Pediat J Garrahan, Buenos Aires, DF, Argentina

[6] Hop Trousseau, Paris, France

[7] Karolinska Inst, Stockholm, Sweden

[8] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany

[9] Texas Childrens Canc & Hematol Ctr, Houston, TX USA

[10] Hosp Sick Children, Toronto, ON, Canada

[11] Sir James Spence Inst, Newcastle Upon Tyne, Tyne & Wear, England

[12] Childrens Natl Med Ctr, Washington, DC USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S16 / S16

页数：1